Indivior Pharmaceuticals, Inc.
INDV
$34.62
-$0.16-0.45%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.33B | 1.29B | 1.24B | 1.18B | 1.17B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.33B | 1.29B | 1.24B | 1.18B | 1.17B |
| Cost of Revenue | 190.00M | 194.00M | 198.00M | 191.00M | 201.00M |
| Gross Profit | 1.14B | 1.10B | 1.04B | 990.00M | 973.00M |
| SG&A Expenses | 532.00M | 568.00M | 579.00M | 599.00M | 599.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -4.00M | -4.00M | -4.00M | -10.00M | -5.00M |
| Total Operating Expenses | 776.00M | 825.00M | 853.00M | 874.00M | 891.00M |
| Operating Income | 556.00M | 466.00M | 387.00M | 307.00M | 283.00M |
| Income Before Tax | 393.00M | 295.00M | 238.00M | 195.00M | 188.00M |
| Income Tax Expenses | 38.00M | 44.00M | 29.00M | 67.00M | 80.00M |
| Earnings from Continuing Operations | 355.00 | 251.00 | 209.00 | 128.00 | 108.00 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 355.00M | 251.00M | 209.00M | 128.00M | 108.00M |
| EBIT | 556.00M | 466.00M | 387.00M | 307.00M | 283.00M |
| EBITDA | 565.00M | 475.00M | 397.00M | 317.00M | 294.00M |
| EPS Basic | 2.90 | 2.02 | 1.68 | 1.02 | 0.86 |
| Normalized Basic EPS | 2.78 | 2.24 | 1.82 | 1.37 | 1.23 |
| EPS Diluted | 2.79 | 1.95 | 1.64 | 1.01 | 0.84 |
| Normalized Diluted EPS | 2.68 | 2.17 | 1.77 | 1.35 | 1.22 |
| Average Basic Shares Outstanding | 492.39M | 498.39M | 498.39M | 500.61M | 507.61M |
| Average Diluted Shares Outstanding | 511.11M | 513.11M | 509.11M | 508.08M | 512.08M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |